

Biovian signs an agreement about early-stage development and manufacturing of a COVID-19 vaccine candidate.

Biovian, a Nordic Bio-CDMO has signed an agreement with a European biopharmaceutical company for contract development and manufacturing of a COVID-19 vaccine. The contract covers the early-stage development and purification of the biological vaccine candidate.

"We are proud to be supporting the global fight against COVID-19" says Dr Knut Ringbom, the CEO of Biovian. "As this virus continues to impact people's lives, we feel privileged to be able to use our expertise in biopharmaceutical manufacturing in such an important project, he continues.

Due to non-disclosure agreements, details of the project are kept confidential.

About Biovian: <http://www.biovian.com/>

Biovian is a One-Stop-Shop Contract Development and Manufacturing Organisation, CDMO of biopharmaceuticals covering GMP services from early development to finished aseptically filled product. Since 2003 Biovian has served a steadily growing stream of satisfied customers with Biopharmaceutical manufacturing excellence supported by broad EMA manufacturing authorisation and successful FDA inspection. Biovian provides premium, reliable and high-quality services on time and within budget. The versatile service offering of the Company supports contract development and manufacturing of biopharmaceuticals using microbial and viral production platforms. The customer products manufactured at Biovian include recombinant proteins, antibody fragments and gene therapy vectors targeted for unmet medical needs.

